Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 7/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2679821 | 0.88 | SMN1; SMN2 (0.51) | MAPTNPC1ALDH1A1POLBRAB9A | |
| SCHEMBL2679819 | 0.88 | SMN1; SMN2 (0.51) | MAPTNPC1ALDH1A1POLBRAB9A | |
| SCHEMBL10054824 | 0.88 | SMN1; SMN2 (0.51) | MAPTNPC1ALDH1A1POLBRAB9A | |
| SCHEMBL10054789 | 0.82 | NAMPT (0.54) | MAPTNPC1RAB9ANAMPT | |
| SCHEMBL10077749 | 0.81 | NAMPT (0.53) | MAPTNPC1RAB9ANAMPT | |
| SCHEMBL2705335 | 0.81 | NAMPT (0.53) | MAPTNPC1RAB9ANAMPT | |
| SCHEMBL10054867 | 0.81 | NAMPT (0.53) | MAPTNPC1RAB9ANAMPT | |
| SCHEMBL2680460 | 0.80 | NAMPT (0.53) | MAPTNPC1RAB9ANAMPT | |
| SCHEMBL10054869 | 0.80 | NAMPT (0.55) | MAPTNPC1RAB9ANAMPT | |
| SCHEMBL2679660 | 0.80 | ALDH1A1 (0.54) | MAPTNPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | ABL1, ABL2, BCR | MAPT 1476/4885NPC1 4708/4885ALDH1A1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.